Advertisement

NCT with Several Agents

  • R. M. Brugger

Abstract

Several protocols are being followed presently to demonstrate the effectiveness of BNCT for treating brain tumors. In these, a compound containing B is injected into the patient and the B selectively collects in the tumor prior to neutron irradiation. For deep brain tumors, when the dose to healthy brain is taken to a maximum limit of tolerance = 12.5 Gy-Eq, the dose to the tumor at the midline of the head may be marginal for sterilizing all cancerous cells. Sometimes, injecting more of the same B compound to increase the dose to the tumor is not practical. The present study considers injecting a second, but different, compound with a different agent which targets the tumor.1 Here, agents means different elements and not several compounds containing B.

Keywords

Neutron Irradiation Neutron Beam Boron Neutron Capture Therapy Gamma Dose Healthy Brain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A.H. Soloway, W. Tjarks, B.A. Barnum, F.-G. Rong, R.F. Barth, I.M. Codogni, and J.G. Wilson, “The chemistry of neutron capture therapy”, Chem. Rev., 98:1515–1562, 1998.PubMedCrossRefGoogle Scholar
  2. 2.
    R.M. Brugger, S. Gibb, J.-L. Shih, S. Pickup, X. Luo, J. Oro, and B. Laster, Estimated doses by gadolinium neutron capture therapy, “Topics in Dosimetry & Treatment Planning for Neutron Capture Therapy”, R.G. Zamenhof, G.R. Solares, and O.K. Harling, ed., Advanced Medical Publications, Madison, Wisconsin, 1994.Google Scholar
  3. 3.
    M.A. Meyer, R.M. Brugger, J.C. Lattimer, K. Kutikkad, A.R. Schoone, and G. Ehrhardt, Non-invasive quantification of Gd uptake in tumors, in “Frontiers in Neutron Capture Therapy,” M.F. Hawthorne, K. Shelly, R.W. Wiersema, eds., Kluwer Academic/Plenum Publishers, New York, 2001, pp. 923–931.CrossRefGoogle Scholar
  4. 4.
    B. Laster, S. Kahl, J. Kirz, L. Warkentein, S. Wirrick, and G. Shani, Receptor-mediated deliver of In and Gd into the tumor cell nucleus by BOPP”, Program and Abstracts of the Eighth International Symposium on NCT for Cancer, La Jolla, CA, 1998, p. 31.Google Scholar
  5. 5.
    S.W. Young, F. Qing, A. Harriman, J.L. Sessler, W.C. Dow, T.D. Mody, G.W. Hemmi, Y. Hao, and R.A. Miller, Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI, Proc. Natl. Acad. Sci. USA, 936:610–615, 1996, Medical Science.Google Scholar
  6. 6.
    A.Z. Diaz, A.D, Chanana, J. Capala, M. Chadha, J.A. Coderre, E.H. Elowitz, J. Iwai, D.D. Joel, H.B. Liu, R. Ma, N. Pendzick, N.S. Press, M.S. Shady, D.N. Slatkin, G.W. Tyson, and L. Wielpolski, Boron neutron capture therapy for glioblastoma multiforme: results from the initial Phase I/II dose escalation studies, in “Frontiers in Neutron Capture Therapy,” M.F. Hawthorne, K. Shelly, R.W. Wiersema, eds., Kluwer Academic/Plenum Publishers, New York, 2001, pp. 61–72.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • R. M. Brugger
    • 1
  1. 1.Nuclear Engineer ProgramUniversity of MissouriColumbiaUSA

Personalised recommendations